ArticleThe Lancet regional health. Western Pacific2026
Progressing towards global hepatitis C elimination: a systematic review and meta-analysis of care cascades in key populations.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Awareness of hepatitis C knowledge among four high-risk populations in Xiamen, China: a cross-sectional study.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis C virus (HCV) remains a global health concern, with cascade gaps hindering elimination. We aim to assess and compare HCV care cascades in four key populations: people living with HIV (PLHIV), people who inject drugs (PWID), men who have sex with men (MSM), and incarcerated individuals. Methods: We conducted a systematic review and meta-analysis of observational studies (Jan 2019-Sept 2025) reporting ≥1 care cascade stage, including screening, confirmatory testing, linkage to care, treatment uptake and completion, and cure, among key populations (PROSPERO CRD42024577740). Four databases were searched. Pooled stage-specific proportions were estimated using random-effects meta-analysis, stratified by population and region. Findings: We included 219 studies (884,450 individuals) from 46 countries. HCV screening coverage remained suboptimal across populations and was lowest in MSM, below 70% in half of countries. Linkage-to-care data were limited yet indicated low linkage in most countries. Treatment uptake was the weakest stage: <70% of PLHIV initiated treatment in 11 of 19 countries, PWID in 16 of 24, MSM in 3 of 10, and incarcerated individuals in 9 of 14. Treatment completion was generally favourable. SVR assessment and SVR among those initiating treatment were lowest in incarcerated individuals, with both indicators falling to about 40% in the poorest-performing countries. Analyses showed better performance in high-income settings. Western Europe performed best, with screening coverage 56.2-87.0%, confirmatory diagnosis 86.8-95.5%, 92.2-97.6% of diagnosed linked to care, and 46.9-79.2% initiating treatment; >90% of those treated completed therapy and >85% were assessed for SVR. In contrast, indicators were substantially worse in lower-income countries, with gaps across stages. Interpretation: Suboptimal HCV screening, weak care linkage, treatment gaps, and regional inequities persist. Enhanced integrated services, better screening, expanded access, and robust data systems are critical to accelerate elimination in resource-limited settings. Funding: National Natural Science Foundation of China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.